Benitec Biopharma (BNTC)

• Market cap: $250M
• 1 day: 4.56%
• 5 days: 4.46%
• 1 month: -4.18%
• 3 months: -2.89%
• 6 months: 20.20%
• Year to date: -10.84%
• 1 year: 277.89%
• 5 years: -87.55%
• 10 years: -92.05%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.

Employees: 16

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

186% more capital invested

Capital invested by funds: $44.3M [Q2] → $127M (+$82.4M) [Q3]

62.0% more ownership

Funds ownership: 67.88% [Q2] → 129.88% (+62.0%) [Q3]

32% more funds holding

Funds holding: 19 [Q2] → 25 (+6) [Q3]

38% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 8

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $17 58% upside
• Avg. target: $24 118% upside
• High target: $30 179% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Baird Brian Skorney 21% 1-year accuracy 5 / 24 met price target	179% upside $30	Outperform Initiated	13 Dec 2024
Guggenheim Debjit Chattopadhyay 21% 1-year accuracy 4 / 19 met price target	58% upside $17	Buy Reiterated	3 Dec 2024